Keytruda monotherapy has increased the overall survival rates. Keeping aside expression of PD-L1, if this treatment is combined with chemotherapy then survival rates are improved up to 23%. Those patients in which tumors expressed PD-L1, and combined positive score (CPS) more than 20 or equal, showed the overall improved survival of 39%. The improvement was 22% where CPS was greater than or equal to 1.
Dr. Barbara Burtness says that in the case of patients with head and neck cancer, where the disease had spread, Keytruda increased the life of patients if taken as a first-line therapy. This is an effective and altered treatment which could help to treat the patients with head and neck cancer. The importance of the research is increased because no such advancement has been made with the previous decade.
The patients who have received surgical removal as a treatment for melanoma where lymph node was involved, can use this drug to fight this disastrous cancer. This drug has been approved by EMA as an adjuvant therapy.
This drug aids to have a stabilized condition where cancer does not occur again. A trial was conducted in collaboration with the European Organization for Research and Treatment of Cancer (EORTC), where the treatment has been encouraged. The recommendation has been done on the basis of an improvement that was actually the recurrence-free survival (RFS) for the drug in pivotal Phase 3 EORTC1325/KEYNOTE-054 trial.
Keytruda combined with chemotherapy can maintain a condition where recurrence of cancer is prohibited.